Javier Crespo

Citée par

	Toutes	Depuis 2020
Citations	30135	19764
indice h	69	56
indice i10	255	189

7000

3500

1750

5250

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025136 264 416 525 515 509 511 486 422 445 444 510 782 753 870 987 1215 1791 2678 3155 3812 6933 1213

Accès public

Tout afficher

120 articles

19 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Emilo Fabrega GarciaFEA Aparato Digestivo. HUMVAdresse e-mail validée de unican.es
José Luis CallejaHospital Universitario Puerta de Hierro MajadahondaAdresse e-mail validée de uam.es
Montserrat RiveroJefe Sección Aparato Digestivo. Medico Hospital Universitario Marques de ValdecillaAdresse e-mail validée de scsalud.es
Marcos López HoyosJefe de Servicio de Inmunología. Hospital Universitario Marqués de Valdecilla-IDIVAL. ProfesorAdresse e-mail validée de scsalud.es
Moises DiagoProfesor Titular de MedicinaAdresse e-mail validée de uv.es
Manuel Romero-GómezCatedrático de Medicina, Universidad de Sevilla.Adresse e-mail validée de us.es
Maria Butí FerretHospital VAlle HebronAdresse e-mail validée de comb.cat
Jeffrey V LazarusCUNY Graduate School of Public Health and Health Policy (CUNY SPH)Adresse e-mail validée de isglobal.org
Hernandez-GuerraProfesor Titular de Universidad de Universidad de La LagunaAdresse e-mail validée de ull.edu.es
Federico Garcia GarciaHead of Clinical Microbiology UnitAdresse e-mail validée de ugr.es
Arun SanyalAdresse e-mail validée de mcvh-vcu.edu
Jose AmadoMédico endocrinólogo y Profesor jubilado de Endocrinologia y NutriciónAdresse e-mail validée de gestion.unican.es
Francisco JorqueraComplejo Asistencial Universitario de León (CAULE)Adresse e-mail validée de saludcastillayleon.es
Jose Maria Sanchez TapiasLiver Unit. Hospital Clinic. BarcelonaAdresse e-mail validée de clinic.cat
Guerra-RuizHospital Universitario ValdecillaAdresse e-mail validée de scsalud.es
Carmen M Sarabia CoboDepartamento de Enfermería, Universidad de Cantabria (ROR 046ffzj20). IDIVALAdresse e-mail validée de unican.es
María Luz MartínezHead Liver Disease Lab , CIC bioGUNEAdresse e-mail validée de cicbiogune.es
Maria Carlota LondoñoHospital ClinicAdresse e-mail validée de clinic.ub.es
Conrado Fernández RodriguezHospital Universitario Fundacion Alcorcon; University Rey Juan Carlos, Madrid, Spain.Adresse e-mail validée de salud.madrid.org
José Luis Hernández HernándezHospital Marqués de Valdecilla. Universidad de CantabriaAdresse e-mail validée de scsalud.es

Suivre

Javier Crespo

Autres nomsJavier Crespo Garcia, https://orcid.org/0000-0001-8248-0172

Jefe Servicio Digestivo. Hospital Universitario Marqués de Valdecilla. Profesor Titular Digestivo

Adresse e-mail validée de humv.es - Page d'accueil

Hepatología. Gastroenterologia.


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023	3054	2023
Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn′ s disease N Inohara, Y Ogura, A Fontalba, O Gutierrez, F Pons, J Crespo, K Fukase, ... Journal of Biological Chemistry 278 (8), 5509-5512, 2003	2220	2003
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018	1864	2018
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. HSA Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal ... New England Journal of Medicine 25 (384(12)), 1113-1124, 2021	1485*	2021
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019	1220	2019
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. SA Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero ... Gastroenterology, 2016	1190*	2016
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. ER Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH ... N Engl J Med 370 (21), 1993-2001, 2014	1041*	2014
Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients J Crespo, A Cayón, P Fernández‐Gil, M Hernández‐Guerra, M Mayorga, ... Hepatology 34 (6), 1158-1163, 2001	960	2001
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine 390 (6), 497-509, 2024	634	2024
Adiponectin and its receptors in non-alcoholic steatohepatitis S Kaser, A Moschen, A Cayon, A Kaser, J Crespo, F Pons-Romero, ... Gut 54 (1), 117-121, 2005	605	2005
Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022	596	2022
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022	480	2022
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment JM Sánchez–Tapias, M Diago, P Escartín, J Enríquez, M Romero–Gómez, ... Gastroenterology 131 (2), 451-460, 2006	478	2006
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020	412	2020
Vitamin D status in hospitalized patients with SARS-CoV-2 infection JL Hernández, D Nan, M Fernandez-Ayala, M García-Unzueta, ... The Journal of Clinical Endocrinology & Metabolism 106 (3), e1343-e1353, 2021	354	2021
Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non … A Guerra Ruiz, F Casafont, J Crespo, A Cayón, M Mayorga, A Estebanez, ... Obesity surgery 17, 1374-1380, 2007	336	2007
Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial J de la Peña, E Brullet, E Sanchez‐Hernández, M Rivero, M Vergara, ... Hepatology 41 (3), 572-578, 2005	288	2005
Metabolomic identification of subtypes of nonalcoholic steatohepatitis C Alonso, D Fernández-Ramos, M Varela-Rey, I Martínez-Arranz, ... Gastroenterology 152 (6), 1449-1461. e7, 2017	277	2017
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression J Barr, J Caballería, I Martínez-Arranz, A Domínguez-Díez, C Alonso, ... Journal of proteome research 11 (4), 2521-2532, 2012	256	2012
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis SA Harrison, Z Goodman, A Jabbar, R Vemulapalli, ZH Younes, B Freilich, ... Journal of hepatology 72 (5), 816-827, 2020	248	2020

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs